

tropanyl ester. This phenomenon may be associated with some geometrical interaction of the two phenyl groups with the large tropanol ring.

Acknowledgment.—We wish to thank Dr. Monis Manning for the analysis of infrared spectra, and Dr. Franklin J. Rosenberg, Sterling-Winthrop Research Institute, for preliminary pharmacological data. The study of absorption of drugs in tumors was supported at the Massachusetts General Hospital by grants from the U. S. Atomic Energy Commission, U. S. Public Health Service, and the John A. Hartford Foundation, Inc.

Tertiary Phosphines and Phosphine Oxides Containing a 2-Haloethyl Group¹

ROBERT F. STRUCK AND Y. FULMER SHEALY


Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama

Received December 16, 1965


2-Haloethyl phosphines and -phosphine oxides may be considered as phosphorus analogs of nitrogen mustards. Heretofore, tertiary phosphine oxides containing a 2-haloethyl group have attracted interest as intermediates for the synthesis of the corresponding vinyl derivatives, which can function as monomers in the synthesis of organophosphorus polymers or copolymers. The existing methods for synthesis of the phosphine oxides, as well as the phosphines, are few in number. The preparation of only one monofunctional 2-haloethyl tertiary phosphine has been described,^{2,3} and in that instance the compound was not obtained in pure form. Abbiss, *et al.*,⁴ have described the synthesis of a bifunctional phosphorus mustard, bis(2-chloroethyl)phenylphosphine oxide, which was obtained in analytical purity, and a related phosphine, bis(2-chloroethyl)phenylphosphine, which was not isolated in pure form. Earlier, Hitchcock and Mann² obtained bis(2-bromoethyl)phenylphosphine hydrobromide as an impure gum. Three synthetic pathways have been reported⁵⁻⁹ for the monofunctional 2-haloethyl phosphine oxides, but only two of these have been used to obtain pure specimens. Because of our interest in obtaining the phosphines and phosphine oxides as characterizable

products that could be evaluated biologically, we have investigated several routes for their preparation.

As mentioned, Hitchcock and Mann² reported the only 2-haloethyl tertiary phosphine heretofore appearing in the literature, 2-bromoethylethylphenylphosphine, as an uncharacterized liquid that was quaternized to a diphosphonium dibromide. We have synthesized 2-chloroethyldiphenylphosphine (I) by addition of lithium diphenylphosphide to excess 1,2-dichloroethane in tetrahydrofuran solution (eq 1). The compound was obtained as a low-melting solid of analytical purity after vacuum distillation and crystallization from petroleum ether. Addition of 1,2-dichloroethane to the phosphide gave only ethylenebis(diphenylphosphine). Earlier, we had synthesized 2-ethoxyethyldiphenylphosphine (II) by treatment of lithium diphenylphosphide with 2-chloroethyl ethyl ether and expected to prepare the 2-haloethyl phosphine (I) by cleavage of the ether linkage followed by halogenation. However, we abandoned further investigation of the latter route since I was obtained by the direct method.



We have used two synthetic pathways to obtain 2-haloethyl tertiary phosphine oxides in analytical purity. 2-Bromoethyldi-*sec*-butyl- and -diphenylphosphine oxides (III and IV, respectively) were conveniently prepared by means of the Michaelis-Arbuzov reaction between excess 1,2-dibromoethane and the appropriate ethyl disubstituted phosphinite (eq 2).



Ethylenebis(disubstituted phosphine oxides) were obtained in low yield as by-products. This method was reported by Rabinowitz and Pellon⁵ who did not attempt purification of the 2-bromoethyl derivatives but dehydrohalogenated them in order to obtain the corresponding vinyl compounds for polymerization studies. Hellmann and Bader⁶ prepared 2-chloroethyldiphenylphosphine oxide as a crystalline solid by the rearrangement of bis(chloromethyl)diphenylphosphonium chloride in aqueous solution, and Kabachnik and co-workers⁷ and Cooper⁸ prepared the same compound in the pure state by the Michaelis-Arbuzov rearrangement of 2-chloroethyl diphenylphosphinite. Miller⁹ reported the preparation of R₂P(O)CH₂CH₂X (R = C₂H₅, C₆H₅, and *n*-C₈H₁₇; X = halogen) by the latter method and their conversion to the corresponding vinyl derivatives but gave no indication as to whether the 2-haloethyl compounds were obtained in pure form.

Our second method, which was used to synthesize 2-bromoethyldimethylphosphine oxide (V) in low yield, is represented by eq 3. Decomposition of the phosphine oxide-magnesium salt complex under mild conditions gave difficultly purifiable mixtures, whereas isolation of 2-ethoxyethyldimethylphosphine oxide (VI) was readily accomplished when the Grignard mixture

(1) This investigation was supported by the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Contract No. PH-43-64-51, and by the C. F. Kettering Foundation.

(2) C. H. S. Hitchcock and F. G. Mann, *J. Chem. Soc.*, 2081 (1958).

(3) Many primary, secondary, and tertiary phosphines have been synthesized in which a halogen is substituted in the 2 position of alkyl groups bonded to phosphorus. The majority of these are polyhalogenated ethyl or higher alkyl derivatives, however, and only the compound reported by Hitchcock and Mann² can be properly categorized as a 2-haloethyl tertiary phosphine. Compound I is the only example of a phosphine of the type R₂PCH₂CH₂-halogen (R = alkyl or aryl) and 2-bromoethylethylphenylphosphine² is the only example of a phosphine of the type RR'PCH₂CH₂-halogen (R and R' = alkyl or aryl but R ≠ R').

(4) T. B. Abbiss, A. H. Soloway, and V. H. Mark, *J. Med. Chem.*, **7**, 763 (1964).

(5) R. Rabinowitz and J. Pellon, *J. Org. Chem.*, **26**, 4623 (1961).

(6) H. Hellmann and J. Bader, *Tetrahedron Letters*, 724 (1961).

(7) M. I. Kabachnik, T. Ya. Medved, Yu. M. Polikarpov, and K. S. Yudina, *Izv. Akad. Nauk SSSR, Otd. Khim. Nauk*, 1584 (1962).

(8) R. S. Cooper, U. S. Patent 3,035,096 (May 15, 1962); *Chem. Abstr.*, **57**, 13805h (1963).

(9) R. C. Miller, Abstracts of Papers, 140th National Meeting of the American Chemical Society, Chicago, Ill., 1961, p 43Q.

infrared spectrum and melting point (270–272°). Reported melting points for the compound are 252–254,^{13c} 276–278,^{13b} 269–270,^{13e} 273–275,^{13d} 267–268.5,^{13c} and 273°.^{13f}

2-Ethoxyethylidimethylphosphine Oxide (VI).—Methylmagnesium iodide was prepared from 10.2 g of Mg and 60 g of methyl iodide in 250 ml of ether. 2-Bromoethylphosphonic dichloride¹¹ (43 g) in 50 ml of ether was added dropwise with stirring at room temperature over a period of 1.5 hr, and the mixture was stirred overnight at room temperature. Ethanolic KOH (60 g in 2000 ml of ethanol) was added with vigorous stirring, and Mg(OH)₂ was removed by filtration. The basic filtrate was refluxed 1 hr, neutralized with concentrated HCl, and filtered, and the filtrate was concentrated *in vacuo*. Distillation *in vacuo* gave 2-ethoxyethylidimethylphosphine oxide (VI), yield 15.3 g (54%), bp 98–101° (0.5 mm). An analytical sample was obtained by redistillation *in vacuo* through a Vigreux column; yield 9.6 g, bp 104–105° (1.5 mm).

Anal. Calcd for C₆H₁₅O₂P: C, 47.99; H, 10.07; P, 20.63. Found: C, 47.99; H, 10.05; P, 20.74.

2-Bromoethylidimethylphosphine Oxide (V).—2-Ethoxyethylidimethylphosphine oxide (VI) (5.1 g) was refluxed with stirring for 4 hr with 20 ml of 48% HBr. The solution was concentrated by distillation at atmospheric pressure, and the last traces of water were removed by evaporation *in vacuo*. The residue in chloroform solution was treated with anhydrous HBr (passed rapidly into the solution) for 4 hr at reflux. After cooling, the lower layer was separated and distilled *in vacuo*; the fraction that boiled in the range 101–122° (0.07–0.5 mm) was collected. The distillate (crystallized in the receiver) was sublimed *in vacuo*, and the sublimate was crystallized three times from CHCl₃ (3, 1, and 1 ml); yield 450 mg (7%), mp 89–90°.

Anal. Calcd for C₄H₁₀BrOP: C, 25.96; H, 5.41; Br, 43.20; P, 16.73. Found: C, 25.76; H, 5.58; Br, 43.37; P, 16.53.

Dimethylvinylphosphine Oxide (VII).—Treatment of methylmagnesium iodide (0.18 mole) with 2-bromoethylphosphonic dichloride¹⁴ (0.09 mole) as described for VI followed by decomposition of the cold (0°) reaction mixture with alcoholic KOH, filtration, neutralization of the filtrate with concentrated HCl, filtration, and concentration of the filtrate *in vacuo* gave a syrupy residue that was distilled *in vacuo*. A fraction was collected with bp 68–69° (1.6 mm); yield 1.83 g (20%); $\bar{\nu}_{\max}$ (in cm⁻¹) 3080, 3030, 2990, 2970, 2905 (CH including CH=CH₂), 1615, 1400 (–CH=CH₂), 1295 (PCH₃), 1165 (P=O); positive test for unsaturation with KMnO₄.

Anal. Calcd for C₄H₈OP: P, 29.74. Found: P, 29.99.

Acknowledgment.—The authors express their appreciation to Dr. J. A. Montgomery for encouragement in this work and to Drs. W. J. Barrett, W. C. Coburn, Jr., P. D. Sternglanz, and members of the Analytical Section of Southern Research Institute who performed the spectral and microanalytical determinations reported. Some of the microanalyses were performed by Galbraith Laboratories, Knoxville, Tenn. Tumor and tissue culture test data were obtained by the Chemotherapy Division of Southern Research Institute under the direction of Drs. F. M. Schabel, Jr., W. R. Laster, Jr., and G. J. Dixon.

(14) G. M. Kosolapoff, *J. Am. Chem. Soc.*, **70**, 1971 (1948); P. A. Rossiiskaya and M. I. Kabachnik, *Izv. Akad. Nauk SSSR, Otd. Khim. Nauk*, 389 (1947).

Glycerol 1,3- and 1,2,4-Butanetriol 1,4-Bismethanesulfonates

PETER W. FEIT AND OLE TVAERMOSE NIELSEN

Leo Pharmaceutical Products, Ballerup, Denmark

Received December 15, 1965

The title compounds were prepared for antitumor screening. Especially 1,2,4-butanetriol 1,4-bismethanesulfonate is closely related to both busulfan and

L-threitol 1,4-bismethanesulfonate;¹ the latter compound possesses antineoplastic activity² and has recently been clinically compared³ with busulfan. The (S)-1,2,4-butanetriol derivative was prepared from diethyl L-maleate. After protection of the hydroxy group the synthesis was based on the principle described¹⁰ for L-threitol 1,4-bismethanesulfonate from diethyl 2,3-O-isopropylidene-L-tartrate.

Screening of these bismethanesulfonates by the Cancer Chemotherapy National Service Center, National Institutes of Health, has revealed no significant inhibition of cell growth in the KB cell culture system. For DL- and (S)-butanetriol bismethanesulfonate a summary of the test data in the Walker carcinoma system is presented in Table I. The glycerol derivative was completely inactive in this system.

TABLE I
SCREENING DATA IN THE WALKER CARCINOSARCOMA 256
(SUBCUTANEOUS) SYSTEM FOR DL- AND
(S)-1,2,4-BUTANETRIOL 1,4-BISMETHANESULFONATE

Config	Daily dose, mg/kg ^a	Survivors	Mean tumor weight (test/control), % ^b	ED ₅₀ ^c mg/kg/day
DL	200	6/6	0	
	100	6/6	0	
	50	5/6	14	57
	25	6/6	93	
(S)	200	6/6	0	
	100	5/6	8	
	50	4/6	78	96
	25	2/6	—	

^a Administered intraperitoneally once daily, days 1 through 5 postinoculation. ^b Sacrificed and evaluated 10 days postinoculation. ^c The dose that inhibits growth to 10% of control growth.

Experimental Section⁴

Glycerol 1,3-Bismethanesulfonate.—A mixture of 1,3-dibromo-2-propanol (21.6 g), silver methanesulfonate (42 g), and acetonitrile (100 ml) was refluxed for 18 hr. After filtration from silver bromide (33 g) and evaporation *in vacuo*, the residue was extracted with acetone leaving unreacted silver methanesulfonate. Addition of 10 N ethanolic HCl (0.1 ml), filtration (decolorizing carbon), evaporation, and recrystallization from ethanol (120 ml, 99.9%) yielded the crude material (7 g), mp 66–67°. Several recrystallizations from ethanol (99.9%) gave the colorless analytically pure compound, mp 66–67°.

Anal. Calcd for C₆H₁₂O₇S₂: C, 24.19; H, 4.87; S, 25.83. Found: C, 24.29; H, 4.95; S, 25.85.

DL-1,2,4-Butanetriol 1,4-Bismethanesulfonate.—To a solution of 1,4-dibromo-2-butanone⁵ (40 g) in diethyl ether (250 ml), a solution of NaBH₄ (2.2 g) in cold water (40 ml) was added dropwise while stirring at 5–8°. The reaction mixture was stirred for an additional 2 hr to attain room temperature. The organic layer was washed with water, dried (MgSO₄), and fractionated *in vacuo*, resulting in slightly impure 1,4-dibromo-2-butanol (24.5 g), bp 110–116° (10 mm). This product (23 g) was treated with silver methanesulfonate for 4 hr as described for 1,3-dibromo-2-propanol. After evaporation of the acetone solution crystallization was effected by treatment with a mixture of diethyl ether–acetone (9:1); yield 7.2 g, mp 72.5–73.5° (ethanol, 99.9%).

(1) (a) P. W. Feit, *Tetrahedron Letters*, 716 (1961); (b) *J. Med. Chem.*, **7**, 14 (1964).

(2) (a) R. Jones, W. B. Kessler, H. E. Lessner, and L. Rane, *Cancer Chemotherapy Rept.*, **10**, 99 (1960); (b) F. R. White, *ibid.*, **24**, 95 (1962).

(3) V. Loeb, Jr., *ibid.*, **42**, 39 (1964).

(4) Analyses by G. Cornali and W. Egger of these laboratories. Melting points were rounded off to half degrees, using a Hershberg apparatus with thermometers subdivided in 0.1°.

(5) J. R. Catch, D. E. Elio, D. H. Hey, and E. R. H. Jones, *J. Chem. Soc.*, 278 (1948).